Skip to main content

Advertisement

SpringerLink
Log in

A new dendritic cell vaccine generated with interleukin-3 and interferon-β induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients

  • Short Communication
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Dendritic cells derived from monocytes cultured in the presence of type I interferon were found to induce efficient T cell responses against tumor antigens in vitro. We vaccinated eight stage III or IV melanoma patients with dendritic cells generated with interferon-β and interleukin-3, activated by poly I: C, and pulsed with the tumor-specific antigen NA17.A2. This dendritic cell vaccine was well-tolerated with only minor and transient flu-like symptoms and inflammatory reactions at the injection sites. In most patients, isotopic imaging documented dendritic cells (DC) migration from the intradermal injection site to the draining lymph nodes. Finally, mixed lymphocyte-peptide culture under limiting dilution conditions followed by tetramer labeling indicated that three out of eight patients mounted a CD8 T cell response against the NA17.A2 antigenic peptide. We conclude that DC generated in type I-IFN represent an interesting alternative to DC generated in IL-4 and GM-CSF for cancer immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Banchereau J, Palucka AK, Dhodapkar M et al (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451–6458

    PubMed  CAS  Google Scholar 

  2. Berzofsky JA, Terabe M, Oh S et al (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113:1515–1525

    Article  PubMed  CAS  Google Scholar 

  3. Blocklet D, Toungouz M, Kiss R et al (2003) 111In-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content. Eur J Nucl Med Mol Imaging 30:440–447

    Article  PubMed  CAS  Google Scholar 

  4. Buelens C, Bartholome EJ, Amraoui Z et al (2002) Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. Blood 99:993–998

    Article  PubMed  CAS  Google Scholar 

  5. Coulie PG, Karanikas V, Colau D et al (2001) A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 98:10290–10295

    Article  PubMed  CAS  Google Scholar 

  6. Cranmer LD, Trevor KT, Hersh EM (2004) Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 53:275–306

    Article  PubMed  Google Scholar 

  7. de Vries IJ, Krooshoop DJ, Scharenborg NM et al (2003) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63:12–17

    PubMed  Google Scholar 

  8. Detournay O, Mazouz N, Goldman M, Toungouz M (2005) IL-6 produced by type I IFN DC controls IFN-gamma production by regulating the suppressive effect of CD4+ CD25+ regulatory T cells. Hum Immunol 66:460–468

    Article  PubMed  CAS  Google Scholar 

  9. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10:475–480

    Article  PubMed  CAS  Google Scholar 

  10. Gjertson DW, Terasaki PI. HLA (1998) American Society for Histocompatibility and Immunogenetics, pp 190–191

  11. Godelaine D, Carrasco J, Lucas S et al (2003) Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171:4893–4897

    PubMed  CAS  Google Scholar 

  12. Guilloux Y, Lucas S, Brichard VG et al (1996) A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 183:1173–1183

    Article  PubMed  CAS  Google Scholar 

  13. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357–2368

    Article  PubMed  CAS  Google Scholar 

  14. Karanikas V, Lurquin C, Colau D et al (2003) Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 171:4898–4904

    PubMed  CAS  Google Scholar 

  15. Lapenta C, Santini SM, Logozzi M et al (2003) Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 198:361–367

    Article  PubMed  CAS  Google Scholar 

  16. Lonchay C, van der BP, Connerotte T et al (2004) Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 101(suppl 2):14631–14638

    Article  PubMed  CAS  Google Scholar 

  17. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al (2004) alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64:5934–5937

    Article  PubMed  CAS  Google Scholar 

  18. Mazouz N, Detournay O, Buelens C et al (2005) Immunostimulatory properties of human dendritic cells generated using IFN-beta associated either with IL-3 or GM-CSF. Cancer Immunol Immunother

  19. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK (1999) Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59:56–58

    PubMed  CAS  Google Scholar 

  20. Paczesny S, Banchereau J, Wittkowski KM, Saracino G, Fay J, Palucka AK (2004) Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med 199:1503–1511

    Article  PubMed  CAS  Google Scholar 

  21. Pardoll D, Allison J (2004) Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 10:887–892

    Article  PubMed  CAS  Google Scholar 

  22. Parlato S, Santini SM, Lapenta C et al (2001) Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98:3022–3029

    Article  PubMed  CAS  Google Scholar 

  23. Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033–1036

    Article  PubMed  CAS  Google Scholar 

  24. Renneson J, Salio M, Mazouz N, Goldman M, Marchant A, Cerundolo V (2005) Mature dendritic cells differentiated in the presence of interferon-beta and interleukin-3 prime functional antigen-specific CD8 T cells. Clin Exp Immunol 139:468–475

    Article  PubMed  CAS  Google Scholar 

  25. Rouas R, Lewalle P, El Ouriaghli F, Nowak B, Duvillier H, Martiat P (2004) Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12. Int Immunol 16:767–773

    Article  PubMed  CAS  Google Scholar 

  26. Santini SM, Lapenta C, Logozzi M et al (2000) Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191:1777–1788

    Article  PubMed  CAS  Google Scholar 

  27. Thurner B, Haendle I, Roder C et al (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669–1678

    Article  PubMed  CAS  Google Scholar 

  28. Tosi D, Valenti R, Cova A et al (2004) Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J Immunol 172:5363–5370

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Ms. C. Van Helleputte and Ms. E. Thille for their expert technical assistance, and Mrs. D. Duriau and A. Manunta for their help in data management. This work was supported by BruCells SA and the government of the Brussels Region.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium

    Myrto Trakatelli, Laurence Gordower & Thierry Velu

  2. Department of Dermatology, Erasme Hospital, Brussels, Belgium

    Myrto Trakatelli, Marianne Laporte & Pierre Vereecken

  3. Cellular and Molecular Therapy Unit, Erasme Hospital, Brussels, Belgium

    Michel Toungouz, Naima Mazouz & Micheline Lambermont

  4. Department of Nuclear Medicine, Erasme Hospital, Brussels, Belgium

    Didier Blocklet & Serge Goldman

  5. Institute of Cellular Pathology, University of Louvain, Brussels, Belgium

    Ygierne Dodoo & Pierre Coulie

  6. Bordet Institute, Brussels, Belgium

    Francois Sales

  7. Department of Dermatology, Huriez Hospital, Lille, France

    Laurent Mortier

  8. Institute of Medical Immunology, Gosselies, Belgium

    Michel Goldman

Authors
  1. Myrto Trakatelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Toungouz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Didier Blocklet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ygierne Dodoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laurence Gordower
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marianne Laporte
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pierre Vereecken
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Francois Sales
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Laurent Mortier
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naima Mazouz
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Micheline Lambermont
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Serge Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Pierre Coulie
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Michel Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Thierry Velu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thierry Velu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trakatelli, M., Toungouz, M., Blocklet, D. et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-β induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother 55, 469–474 (2006). https://doi.org/10.1007/s00262-005-0056-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-005-0056-z

Keywords

Search

Navigation